{
    "2018-06-01": [
        [
            {
                "time": "2018-05-07",
                "original_text": "Lilly gets U.S. nod for arthritis drug, sets price well below rivals",
                "features": {
                    "keywords": [
                        "Lilly",
                        "U.S. nod",
                        "arthritis drug",
                        "price below rivals"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-13",
                "original_text": "FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis",
                "features": {
                    "keywords": [
                        "FDA",
                        "OLUMIANT",
                        "baricitinib",
                        "Rheumatoid Arthritis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-14",
                "original_text": "FDA approves lower dose of Lilly-Incyte arthritis drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "lower dose",
                        "Lilly-Incyte",
                        "arthritis drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-10",
                "original_text": "A Closer Look at Novartis’s Innovative Medicine Business",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Innovative Medicine"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-18",
                "original_text": "Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Digestive Disease Week",
                        "Mirikizumab",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "Can Nektar Therapeutics Disrupt This $20 Billion Market?",
                "features": {
                    "keywords": [
                        "Nektar Therapeutics",
                        "Disrupt",
                        "$20 Billion Market"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}